Advanced NanoTherapies’ SirPlux Duo Drug-Coated Balloon Receives FDA Breakthrough Designation for Small Vessel Coronary Artery Disease
LOS GATOS, CA – September 19th, 2022 – Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease’s most significant challenges through the creative applications of nanotechnology, today announced the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its SirPlux Duo Drug-Coated Balloon (DCB) for coronary artery disease in vessels less than 3.0mm. This achievement comes only weeks after the company received two other critical Breakthrough Device designations for its SirPlux Duo DCB in coronary in-stent restenosis (ISR) and peripheral below-the-knee (BTK) lesions.
Cleveland Clinic-Led Trial Finds That Cerebral Embolic Protection Device Reduced Risk of Disabling Stroke Following TAVR Procedure
Findings from a Cleveland Clinic-led trial show that a Cerebral Embolic Protection (CEP) device reduced the risk of disabling strokes by capturing and removing tiny pieces of calcium and other fragments resulting from transcatheter aortic valve replacement (TAVR) before they can reach the brain.
Imaging advances, targeted therapies improve outlook for recurrent pericarditis
Advances in imaging techniques and new treatments are changing the management of recurrent pericarditis, improving outcomes for patients with formerly treatment-resistant disease, researchers reported.